1887

Abstract

are among the most common bacteria isolated in hospital infections, especially in developing countries. Multi-drug, extended-drug or pan-drug resistance makes treatment a real medical challenge. In the present review, the authors describe clinical and experimental data in order to present different current and potential future strategies to treat infections caused by multi-drug-resistant . The therapeutic options for carbapenem-resistant are scarce, and the current options have poor pharmacokinetic aspects and several side effects. Combined therapy has been an alternative for multi-drug-resistant . However, this issue is always controversial. In some studies combined therapy has shown superiority for some strains of in animal models and studies. However, studies with humans are scarce and too poor quality to suggest the best approach for the treatment of infections caused by multi-drug-resistant .

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000144
2015-09-01
2019-10-17
Loading full text...

Full text loading...

/deliver/fulltext/jmm/64/9/951.html?itemId=/content/journal/jmm/10.1099/jmm.0.000144&mimeType=html&fmt=ahah

References

  1. Alp E. , Esel D. , Yildiz O. , Voss A. , Melchers W. , Doganay M. . ( 2006;). Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital. Scand J Infect Dis 38: 335–340 [CrossRef] [PubMed].
    [Google Scholar]
  2. Arroyo L. A. , Mateos I. , González V. , Aznar J. . ( 2009;). In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 53: 1295–1296 [CrossRef] [PubMed].
    [Google Scholar]
  3. Bassetti M , Repetto E. , Righi E. , Boni S. , Diverio M. , Molinari M. P. , Mussap M. , Artioli S. , Ansaldi F. , Durando P. , Orengo G. , Bobbio Pallavicini F. , Viscoli C. . ( 2003;). Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61: 417–20.[CrossRef]
    [Google Scholar]
  4. Baumgart A. M. , Molinari M. A. , Silveira A. C. . ( 2010;). Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14: 433–436 [CrossRef] [PubMed].
    [Google Scholar]
  5. Bernabeu-Wittel M. , Pichardo C. , García-Curiel A. , Pachón-Ibáñez M. E. , Ibáñez-Martínez J. , Jiménez-Mejías M. E. , Pachón J. . ( 2005;). Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 11: 319–325 [CrossRef] [PubMed].
    [Google Scholar]
  6. Cereda R. F. , Azevedo H. D. , Girardello R. , Xavier D. E. , Gales A. C. , INVITA-A-CEFTO Brazilian Study Group . ( 2011;). Antimicrobial activity of ceftobiprole against Gram-negative and Gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study. Braz J Infect Dis 15: 339–348 [CrossRef] [PubMed].
    [Google Scholar]
  7. Chang S. C. , Chen Y. C. , Luh K. T. , Hsieh W. C. . ( 1995;). In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Diagn Microbiol Infect Dis 23: 105–110 [CrossRef] [PubMed].
    [Google Scholar]
  8. Choi M. J. , Park Y. K. , Peck K. R. , Ko K. S. . ( 2014;). Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents 44: 475–476 [CrossRef] [PubMed].
    [Google Scholar]
  9. Christie C. , Mazon D. , Hierholzer W. Jr , Patterson J. E. . ( 1995;). Molecular heterogeneity of Acinetobacter baumanii isolates during seasonal increase in prevalence. Infect Control Hosp Epidemiol 16: 590–594 [CrossRef] [PubMed].
    [Google Scholar]
  10. Chu H. , Zhao L. , Wang M. , Liu Y. , Gui T. , Zhang J. . ( 2013;). Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 17: 389–394 [CrossRef] [PubMed].
    [Google Scholar]
  11. Cieslinski J. M. , Arend L. , Tuon F. F. , Silva E. P. , Ekermann R. G. , Dalla-Costa L. M. , Higgins P. G. , Seifert H. , Pilonetto M. . ( 2013;). Molecular epidemiology characterization of OXA-23 carbapenemase-producing Acinetobacter baumannii isolated from 8 Brazilian hospitals using repetitive sequence-based PCR. Diagn Microbiol Infect Dis 77: 337–340 [CrossRef] [PubMed].
    [Google Scholar]
  12. Corrêa L. L. , Botelho L. A. , Barbosa L. C. , Mattos C. S. , Carballido J. M. , de Castro C. L. , Mondino P. J. , de Paula G. R. , de Mondino S. S. , de Mendonça-Souza C. R. . ( 2012;). Detection of bla OXA-23 in Acinetobacter spp. isolated from patients of a university hospital. Braz J Infect Dis 16: 521–526 [CrossRef] [PubMed].
    [Google Scholar]
  13. Cullmann W. , Opferkuch W. , Stieglitz M. , Werkmeister U. . ( 1982;). A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed beta-lactam derivatives. Antimicrob Agents Chemother 22: 302–307 [CrossRef] [PubMed].
    [Google Scholar]
  14. Curcio D. , Fernández F. , Cané A. , Barcelona L. , Stamboulian D. . ( 2008;). Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 12: 198–201 [CrossRef] [PubMed].
    [Google Scholar]
  15. Dalla-Costa L. M. , Coelho J. M. , Souza H. A. , Castro M. E. , Stier C. J. , Bragagnolo K. L. , Rea-Neto A. , Penteado-Filho S. R. , Livermore D. M. , Woodford N. . ( 2003;). Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 41: 3403–3406 [CrossRef] [PubMed].
    [Google Scholar]
  16. Drago L. , De Vecchi E. , Nicola L. , Tocalli L. , Gismondo M. R. . ( 2005;). In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with β-lactams and amikacin. J Antimicrob Chemother 56: 353–359 [CrossRef] [PubMed].
    [Google Scholar]
  17. Dync G. , Demiraslan H. , Elmali F. , Ahmed S. S. , Alp E. , Doganay M. . ( 2015;). Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. New Microbiol 38: 67–73.
    [Google Scholar]
  18. Gales A. C. , Azevedo H. D. , Cereda R. F. , Girardello R. , Xavier D. E. , INVITA-A-DORI Brazilian Study Group . ( 2011;). Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study. Braz J Infect Dis 15: 513–520 [CrossRef] [PubMed].
    [Google Scholar]
  19. Giamarellou H. , Sfikakis P. , Voutsinas D. , Galanakis N. , Daikos G. K. . ( 1986;). Evaluation of imipenem/cilastatin against nosocomial infections and multiresistant pathogens. J Antimicrob Chemother 18: (Suppl. E), 175–179.
    [Google Scholar]
  20. Go E. S. , Urban C. , Burns J. , Kreiswirth B. , Eisner W. , Mariano N. , Mosinka-Snipas K. , Rahal J. J. . ( 1994;). Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344: 1329–1332 [CrossRef] [PubMed].
    [Google Scholar]
  21. Guarnacho-Montero J. , Ortiz-Leyba C. , Jiménez-Jiménez F. J. , Barrero-Almodóvar A. E. , García-Garmendia J. L. , Bernabeu-Wittell M. , Gallego-Lara S. L. , Madrazo-Osuna J. . ( 2013;). Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36: 1111–8.[CrossRef]
    [Google Scholar]
  22. Guner R. , Hasanoglu I. , Keske S. , Kalem A. K. , Tasyaran M. A. . ( 2011;). Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39: 515–8.[CrossRef]
    [Google Scholar]
  23. Heyland D. K. , Dodek P. , Muscedere J. , Day A. , Cook D. , Canadian Critical Care Trials Group . ( 2008;). Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 36: 737–744 [CrossRef] [PubMed].
    [Google Scholar]
  24. Hogg G. M. , Barr J. G. , Webb C. H. . ( 1998;). In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii . J Antimicrob Chemother 41: 494–495 [CrossRef] [PubMed].
    [Google Scholar]
  25. Hornsey M. , Wareham D. W. . ( 2011;). In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 55: 3534–3537 [CrossRef] [PubMed].
    [Google Scholar]
  26. Hornsey M. , Longshaw C. , Phee L. , Wareham D. W. . ( 2012;). In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother 56: 3080–3085 [CrossRef] [PubMed].
    [Google Scholar]
  27. Hornsey M. , Phee L. , Longshaw C. , Wareham D. W. . ( 2013;). In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents 41: 285–287 [CrossRef] [PubMed].
    [Google Scholar]
  28. Joly-Guillou M. L. , Bergogne-Berezin E. , Vieu J. F. . ( 1990;). [Epidemiology of Acinetobacter and resistance to antibiotics at hospitals. A 5-year evaluation]. Presse Med 19: 357–361 (in French) [PubMed].
    [Google Scholar]
  29. Joly-Guillou M. L. , Wolff M. , Farinotti R. , Bryskier A. , Carbon C. . ( 2000;). In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother 46: 827–830 [CrossRef] [PubMed].
    [Google Scholar]
  30. Kiffer C. R. , Sampaio J. L. , Sinto S. , Oplustil C. P. , Koga P. C. , Arruda A. C. , Turner P. J. , Mendes C. . ( 2005;). In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii . Diagn Microbiol Infect Dis 52: 317–322 [CrossRef] [PubMed].
    [Google Scholar]
  31. Kitzis M. D. , Goldstein F. W. , Labia R. , Acar J. F. . ( 1983;). [Activity of sulbactam and clavulanic acid, alone and combined, on Acinetobacter calcoaceticus]. Ann Microbiol (Paris) 134A: 163–168 (in French). [PubMed].
    [Google Scholar]
  32. Kuo L. C. , Lai C. C. , Liao C. H. , Hsu C. K. , Chang Y. L. , Chang C. Y. , Hsueh P. R. . ( 2007;). Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 13: 196–198 [CrossRef] [PubMed].
    [Google Scholar]
  33. Lee Y. T. , Tsao S. M. , Hsueh P. R. . ( 2013;). Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32: 1211–1220 [CrossRef] [PubMed].
    [Google Scholar]
  34. Levin A. S. , Barone A. A. , Penço J. , Santos M. V. , Marinho I. S. , Arruda E. A. , Manrique E. I. , Costa S. F. . ( 1999;). Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii . Clin Infect Dis 28: 1008–1011 [CrossRef] [PubMed].
    [Google Scholar]
  35. Levin A. S. , Levy C. E. , Manrique A. E. , Medeiros E. A. , Costa S. F. . ( 2003;). Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 21: 58–62 [CrossRef] [PubMed].
    [Google Scholar]
  36. Lim T. P. , Tan T. Y. , Lee W. , Sasikala S. , Tan T. T. , Hsu L. Y. , Kwa A. L. . ( 2011;). In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6: e18485 [CrossRef] [PubMed].
    [Google Scholar]
  37. Lima A. L. , Oliveira P. R. , Paula A. P. , Dal-Paz K. , Almeida J. N. Jr , Félix C. S. , Rossi F. . ( 2011;). Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis 15: 1–5 [CrossRef] [PubMed].
    [Google Scholar]
  38. Magiorakos A. P. , Srinivasan A. , Carey R. B. , Carmeli Y. , Falagas M. E. , Giske C. G. , Harbarth S. , Hindler J. F. , Kahlmeter G. , other authors . ( 2012;). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268–281 [CrossRef] [PubMed].
    [Google Scholar]
  39. Markou N. , Apostolakos H. , Koumoudiou C. , Athanasiou M. , Koutsoukou A. , Alamanos I. , Gregorakos L. . ( 2003;). Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7: R78–R83 [CrossRef] [PubMed].
    [Google Scholar]
  40. Martinez-Martinez L. , Rodriguez G. , Pascual A. , Suárez A. I. , Perea E. J. . ( 1996;). In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii . J Antimicrob Chemother 38: 1107–1108 [CrossRef] [PubMed].
    [Google Scholar]
  41. Medell M. , Hart M. , Marrero O. , Espinosa F. , Montes de Oca Z. , Valdés R. . ( 2012;). Clinical and microbiological characterization of pneumonia in mechanically ventilated patients. Braz J Infect Dis 16: 442–447 [CrossRef] [PubMed].
    [Google Scholar]
  42. Metan G. , Alp E. , Aygen B. , Sumerkan B. . ( 2007;). Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 60: 197–199 [CrossRef] [PubMed].
    [Google Scholar]
  43. Michalopoulos A. S. , Tsiodras S. , Rellos K. , Mentzelopoulos S. , Falagas M. E. . ( 2005;). Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11: 115–121 [CrossRef] [PubMed].
    [Google Scholar]
  44. Motaouakkil S. , Charra B. , Hachimi A. , Benslama A. . ( 2006a;). [Nosocomial pneumonia caused by multiresistant Acinetobacter baumanii treated by colistin and rifampicin]. Ann Fr Anesth Reanim 25: 543–544 (in French). [CrossRef] [PubMed].
    [Google Scholar]
  45. Motaouakkil S. , Charra B. , Hachimi A. , Nejmi H. , Benslama A. , Elmdaghri N. , Belabbes H. , Benbachir M. . ( 2006b;). Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii . J Infect 53: 274–278 [CrossRef] [PubMed].
    [Google Scholar]
  46. Mukhopadhyay C. , Krishna S. , Vandana K. E. , Shenoy A. , Bairy I. . ( 2008;). Ventilator-associated pneumonia with Col-S strains: a successful comeback of colistin!. Braz J Infect Dis 12: 444–446 [CrossRef] [PubMed].
    [Google Scholar]
  47. Mutlu Yilmaz E. , Sunbul M. , Aksoy A. , Yilmaz H. , Guney A. K. , Guvenc T. . ( 2012;). Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii . Int J Antimicrob Agents 40: 332–336 [CrossRef] [PubMed].
    [Google Scholar]
  48. Ni W. , Shao X. , Di X. , Cui J. , Wang R. , Liu Y. . ( 2015;). In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 45: 8–18 [CrossRef] [PubMed].
    [Google Scholar]
  49. Oliveira M. S. , Prado G. V. , Costa S. F. , Grinbaum R. S. , Levin A. S. . ( 2008;). Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61: 1369–1375 [CrossRef] [PubMed].
    [Google Scholar]
  50. Ouderkirk J. P. , Nord J. A. , Turett G. S. , Kislak J. W. . ( 2003;). Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 47: 2659–2662 [CrossRef] [PubMed].
    [Google Scholar]
  51. Pantopoulou A. , Giamarellos-Bourboulis E. J. , Raftogannis M. , Tsaganos T. , Dontas I. , Koutoukas P. , Baziaka F. , Giamarellou H. , Perrea D. . ( 2007;). Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29: 51–55 [CrossRef] [PubMed].
    [Google Scholar]
  52. Peleg A. Y. , Jara S. , Monga D. , Eliopoulos G. M. , Moellering R. C. Jr , Mylonakis E. . ( 2009;). Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 53: 2605–2609 [CrossRef] [PubMed].
    [Google Scholar]
  53. Petrosillo N. , Chinello P. , Proietti M. F. , Cecchini L. , Masala M. , Franchi C. , Venditti M. , Esposito S. , Nicastri E. . ( 2005;). Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11: 682–683 [CrossRef] [PubMed].
    [Google Scholar]
  54. Pilonetto M. , Rosa E. A. , Brofman P. R. , Baggio D. , Calvário F. , Schelp C. , Nascimento A. , Messias-Reason I. . ( 2004;). Hospital gowns as a vehicle for bacterial dissemination in an intensive care unit. Braz J Infect Dis 8: 206–210 [CrossRef] [PubMed].
    [Google Scholar]
  55. Principe L. , D'Arezzo S. , Capone A. , Petrosillo N. , Visca P. . ( 2009;). In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii . Ann Clin Microbiol Antimicrob 8: 18 [CrossRef] [PubMed].
    [Google Scholar]
  56. Raka L. , Kalenć S. , Bosnjak Z. , Budimir A. , Katić S. , Sijak D. , Mulliqi-Osmani G. , Zoutman D. , Jaka A. . ( 2009;). Molecular epidemiology of Acinetobacter baumannii in central intensive care unit in Kosova Teaching Hospital. Braz J Infect Dis 13: 408–413 [PubMed].
    [Google Scholar]
  57. Rodríguez-Hernández M. J. , Pachón J. , Pichardo C. , Cuberos L. , Ibáñez-Martínez J. , García-Curiel A. , Caballero F. J. , Moreno I. , Jiménez-Mejías M. E. . ( 2000;). Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 45: 493–501 [CrossRef] [PubMed].
    [Google Scholar]
  58. Romanelli R. M. , Jesus L. A. , Clemente W. T. , Lima S. S. , Rezende E. M. , Coutinho R. L. , Moreira R. L. , Neves F. A. , Brás N. J. . ( 2009;). Outbreak of resistant Acinetobacter baumannii – measures and proposal for prevention and control. Braz J Infect Dis 13: 341–347 [CrossRef] [PubMed].
    [Google Scholar]
  59. Rossi F. , García P. , Ronzon B. , Curcio D. , Dowzicky M. J. . ( 2008;). Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis 12: 405–415 [CrossRef] [PubMed].
    [Google Scholar]
  60. Sader H. S. . ( 2000;). Antimicrobial resistance in Brazil: comparison of results from two multicenter studies. Braz J Infect Dis 4: 91–99 [PubMed].
    [Google Scholar]
  61. Sader H. S. , Jones R. N. . ( 2005;). Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents 25: 380–384 [CrossRef] [PubMed].
    [Google Scholar]
  62. Sader H. S. , Sampaio J. L. , Zoccoli C. , Jones R. N. . ( 1999;). Results of the 1997 SENTRY antimicrobial surveillance program in three Brazilian medical centers. Braz J Infect Dis 3: 63–79 [PubMed].
    [Google Scholar]
  63. Sader H. S. , Gales A. C. , Pfaller M. A. , Mendes R. E. , Zoccoli C. , Barth A. , Jones R. N. . ( 2001;). Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY antimicrobial surveillance program. Braz J Infect Dis 5: 200–214 [CrossRef] [PubMed].
    [Google Scholar]
  64. Santimaleeworagun W. , Wongpoowarak P. , Chayakul P. , Pattharachayakul S. , Tansakul P. , Garey K. W. . ( 2011;). In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 42: 890–900 [PubMed].
    [Google Scholar]
  65. Savov E. , Chankova D. , Vatcheva R. , Dinev N. . ( 2002;). In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sumbactam alone and in combination with amikacin. Int J Antimicrob Agents 20: 390–2.[CrossRef]
    [Google Scholar]
  66. Sengstock D. M. , Thyagarajan R. , Apalara J. , Mira A. , Chopra T. , Kaye K. S. . ( 2010;). Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 50: 1611–1616 [CrossRef] [PubMed].
    [Google Scholar]
  67. Simsek F. , Gedik H. , Yildirmak M. T. , Iris N. E. , Turkmen A. , Ersoy A. , Ersoz M. , Gucuyener A. . Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy?. Indian J Med Microbiol 30: 448–52.
    [Google Scholar]
  68. Sobieszczyk M. E. , Furuya E. Y. , Hay C. M. , Pancholi P. , Della-Latta P. , Hammer S. M. , Kubin C. J. . ( 2004;). Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54: 566–569 [CrossRef] [PubMed].
    [Google Scholar]
  69. Song J. Y. , Cheong H. J. , Lee J. , Sung A. K. , Kim W. J. . ( 2009;). Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 33: 33–39 [CrossRef] [PubMed].
    [Google Scholar]
  70. Tankovic J. , Legrand P. , De Gatines G. , Chemineau V. , Brun-Buisson C. , Duval J. . ( 1994;). Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 32: 2677–2681 [PubMed].
    [Google Scholar]
  71. Tascini C. , Menichetti F. , Bozza S. , Del Favero A. , Bistoni F. . ( 1998;). Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii . J Antimicrob Chemother 42: 270–271 [CrossRef] [PubMed].
    [Google Scholar]
  72. Teo F. , Jim T. P. , Hsu L. Y. , Tan T. Y. , Sasikala S. , Hon P. Y. , Kwa A. L. , Apisarnthanarak A. . ( 2015;). Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist Infect Control 4:2
    [Google Scholar]
  73. Timurkaynak F. , Can F. , Azap O. K. , Demirbilek M. , Arslan H. , Karaman S. O. . ( 2006;). In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27: 224–228 [CrossRef] [PubMed].
    [Google Scholar]
  74. Toledo P. V. , Arend L. N. , Pilonetto M. , Costa Oliveira J. C. , Luhm K. R. , Working Group in Healthcare Associated Infections (WGHAI) . ( 2012;). Surveillance programme for multidrug-resistant bacteria in healthcare-associated infections: an urban perspective in South Brazil. J Hosp Infect 80: 351–353 [CrossRef] [PubMed].
    [Google Scholar]
  75. Tuon F. F. , Penteado-Filho S. R. , Amarante D. , Andrade M. A. , Borba L. A. . ( 2010a;). Mortality rate in patients with nosocomial Acinetobacter meningitis from a Brazilian hospital. Braz J Infect Dis 14: 437–440 [CrossRef] [PubMed].
    [Google Scholar]
  76. Tuon F. F. , Penteado-Filho S. R. , Amarante D. , Andrade M. A. , Borba L. A. . ( 2010b;). Mortality rate in patients with nosocomial Acinetobacter meningitis from a Brazilian hospital. Braz J Infect Dis 14: 437–440 [CrossRef] [PubMed].
    [Google Scholar]
  77. Tuon F. F. , Rymsza A. M. , Penteado-Filho S. R. , Pilonetto M. , Arend L. N. , Levin A. S. . ( 2011;). Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter?. J Infect 62: 246–249 [CrossRef] [PubMed].
    [Google Scholar]
  78. Tuon F. F. , Rigatto M. H. , Lopes C. K. , Kamei L. K. , Rocha J. L. , Zavascki A. P. . ( 2014;). Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43: 349–352 [CrossRef] [PubMed].
    [Google Scholar]
  79. Urban C. , Go E. , Mariano N. , Berger B. J. , Avraham I. , Rubin D. , Rahal J. J. . ( 1993;). Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus . J Infect Dis 167: 448–451 [CrossRef] [PubMed].
    [Google Scholar]
  80. Villegas M. V. , Briceno D. F. , Ruiz S. J. , Furtado G. H. , Nicolau D. P. . ( 2011;). Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Braz J Infect Dis 15: 413–419 [CrossRef] [PubMed].
    [Google Scholar]
  81. Wareham D. W. , Bean D. C. . ( 2006;). In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 5: 10 [CrossRef] [PubMed].
    [Google Scholar]
  82. Wolff M. , Joly-Guillou M. L. , Farinotti R. , Carbon C. . ( 1999;). In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 43: 1406–1411 [PubMed].
    [Google Scholar]
  83. Wood C. A. , Reboli A. C. . ( 1993;). Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus . J Infect Dis 168: 1602–1603 [CrossRef] [PubMed].
    [Google Scholar]
  84. Yadav R. , Landersdorfer C. B. , Nation R. L. , Boyce J. D. , Bulitta J. B. . ( 2015;). Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii . Antimicrob Agents Chemother 59: 2286–2298 [CrossRef] [PubMed].
    [Google Scholar]
  85. Zavascki A. P. , Goldani L. Z. , Cao G. , Superti S. V. , Lutz L. , Barth A. L. , Ramos F. , Boniatti M. M. , Nation R. L. , Li J. . ( 2008;). Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47: 1298–1304 [CrossRef] [PubMed].
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000144
Loading
/content/journal/jmm/10.1099/jmm.0.000144
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error